<DOC>
	<DOCNO>NCT00754793</DOCNO>
	<brief_summary>The study hypothesis addition antidepressant standard treatment regimen patient chronic sinusitis depression facial pain disorder depression decrease report chronic sinusitis facial pain symptom severity . This stratify , randomize , double-blind , placebo-controlled study use drug escitalopram treatment depression patient experience depression chronic sinusitis depression facial pain disorder . It 12-week study . Subjects screen visit follow phone weekly four week bi-weekly 8 week .</brief_summary>
	<brief_title>Sinusitis Facial Pain Disorders Anti-Depression Trial</brief_title>
	<detailed_description>All patient present University Washington Medical Center Sinus Clinic screen depression PHQ-9 standard care evaluation , well physical examination , nasal endoscopy , CT scan . Those patient meet diagnostic criterion CRS major depression treat three week maximal medical therapy . Maximal medical therapy include three week second-line antibiotic ( Augmentin , azithromycin , fluoroquinolone ) , possible oral steroid base presence inflammation polyp sinus , nasal saline irrigation . They follow Dr. Davis one month initial evaluation . Those still significantly improve symptom ( consider medical failure ) approach introduce study Dr. Davis 's medical assistant refer research assistant discussion offer enrollment consent entry criterion meet . Note patient present initial consultation receive maximal medical therapy refer clinician within past two month , approach possible entry study time . Patients present complaint facial discomfort also include . These people often present subjective sinusitis-like symptom objectively support CT scan endoscopy . These patient refer Neurology Clinic ask defer appt . duration study . Both patient clinician blind drug assignment . Subjects stratify accord facial pain chronic sinusitis randomization do restrict block randomization . A letter send patient 's primary care provider explain trial patient may take anti-depressant placebo . During trial , dose escitalopram start 10mg per day seven day follow 20mg per day fourteen day , maintain titrate base study 's titration protocol . At conclusion three month active drug , patient give opportunity continue medication primary care provider . A two week supply active anti-depressant available buffer transition patient 's randomized escitalopram . Data Collection Phase 0 : Recruitment All patient meet criterion CRS depression facial pain depression monitor determine many patient exclude reason . This imperative Specific Aim 1 , collect data necessary eventually calculate sample size recruitment time future definitive trial . Phase I : Patient Baseline Initial clinical , radiographic , co-morbid characteristic identify use questionnaire short personal interview ( study research assistant ) describe immediately follow initial one-month follow-up visit Dr. Davis Phase II : Patient Follow-up Subjects follow closely weekly phone call research assistant first four week trial . During event , PHQ-9 administer question ask regard adverse event side effect . After , subject telephone bi-weekly duration trial ask question . In addition , one month three month initiation research drug , telephone interview , subject administer four questionnaire : SNOT-20 , SF-12 , PHQ-9 , SCL-20 . Chronic sinusitis subject facial pain subject complete identical form common symptom crossover .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Facies</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Facial Pain</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>meet diagnostic criterion chronic sinusitis meet diagnostic criterion facial pain disorder meet criterion major depressive disorder PHQ9 18 year age old establish primary care provider able read speak English unable give inform consent unable complete selfadministered questionnaire due cognitive impairment , language barrier severe medical condition terminal illness significantly immunocompromized complication chronic rhinosinusitis presence sinus tumor isolate sphenoid disease immotile cilia syndrome currently antidepressant mood stabilizer med . diagnosis bipolar disorder , schizophrenic disorder , paranoid disorder , psychotic disorder NOS significant suicide risk history hospitalization mental disorder include psychosis depression history drug abuse within prev . 6 month dependency drug , include alcohol pregnant breast feed woman childbearing potential currently use approve method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>